Ernexa Therapeutics Inc. (ERNA)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.5M | -2.0M | -2.1M | -3.5M |
| Net Income | -3.1M | -1.2M | -1.5M | -5.5M |
| Diluted EPS | $-15.25 | $-3.75 | $nan | $-173.75 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 68K | 582K | 0.00 |
| Gross Profit | 0.00 | -168K | 486K | 0.00 |
| Operating Income | -26.9M | -20.7M | -17.2M | -9.3M |
| Net Income | -24.6M | -21.7M | -44.5M | -14.1M |
| Diluted EPS | $-3,022.50 | $-1,530.00 | $-1,224.00 | $-56.00 |